Log in

NASDAQ:VTGN - Vistagen Therapeutics Stock Price, Forecast & News

$0.65
-0.06 (-8.45 %)
(As of 02/17/2020 04:50 AM ET)
Add
Today's Range
$0.61
Now: $0.65
$0.74
50-Day Range
$0.65
MA: $0.72
$0.80
52-Week Range
$0.29
Now: $0.65
$1.66
Volume350,631 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VTGN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees9
Next Earnings Date6/23/2020 (Estimated)
OptionableNot Optionable

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.


Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, February, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.08. View Vistagen Therapeutics' Earnings History.

When is Vistagen Therapeutics' next earnings date?

Vistagen Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, June 23rd 2020. View Earnings Estimates for Vistagen Therapeutics.

What price target have analysts set for VTGN?

3 brokers have issued 1 year price targets for Vistagen Therapeutics' stock. Their forecasts range from $0.70 to $4.00. On average, they expect Vistagen Therapeutics' stock price to reach $2.35 in the next twelve months. This suggests a possible upside of 261.5% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.

What is the consensus analysts' recommendation for Vistagen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vistagen Therapeutics.

What are Wall Street analysts saying about Vistagen Therapeutics stock?

Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
  • 1. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019)
  • 2. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/11/2019)

Has Vistagen Therapeutics been receiving favorable news coverage?

Media headlines about VTGN stock have trended somewhat positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vistagen Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Vistagen Therapeutics.

Are investors shorting Vistagen Therapeutics?

Vistagen Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,640,000 shares, a decrease of 8.3% from the January 15th total of 2,880,000 shares. Based on an average daily trading volume, of 817,900 shares, the days-to-cover ratio is presently 3.2 days. Approximately 7.0% of the shares of the company are short sold. View Vistagen Therapeutics' Current Options Chain.

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Matinas BioPharma (MTNB), vTv Therapeutics (VTVT), Lithium Americas (LAC), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP) and Nabriva Therapeutics (NBRV).

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the folowing people:
  • Mr. Shawn K. Singh, CEO & Director (Age 56)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
  • Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 64)

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Blair William & Co. IL (0.12%). Company insiders that own Vistagen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe. View Institutional Ownership Trends for Vistagen Therapeutics.

Which major investors are selling Vistagen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Vistagen Therapeutics.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.65.


MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel